COMP <GO>
BIIB vs LLY // RSI-14 & 200D SMA MOMENTUM
Biogen Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: BIIB 3
— LLY 12
▲ RSI-14 & 200D SMA MOMENTUM LEADER: LLY
LAST: $253.62 (+1.59%) • MKT CAP: $36.90B
rsi-technicals
66.7
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
rsi-technicals
77.9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BIIB VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BIIB | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 75.70% | 83.64% | -7.94 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 6.40% | 32.36% | -25.96 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 22.3x | 36.4x | -14.12 | BIIB | /valuation <GO> |
| Free Cash Flow Yield | 5.56% | 2.30% | +3.26 | BIIB | /fcf-yield <GO> |
| Operating Margin | 15.90% | 40.21% | -24.31 | LLY | /operating-margins <GO> |
| Net Profit Margin | 13.10% | 31.90% | -18.80 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 2.20% | 45.51% | -43.31 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.70 | 9.29 | -5.59 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 9/9 | -2.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 6.77% | +0.43 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 66.7 | 77.9 | -11.23 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.10 | 0.51 | +0.59 | BIIB | /macro-sensitivity <GO> |
| Forward P/E Multiple | 26.5x | 26.3x | +0.25 | LLY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $36.90B | $1.33T | -$1.30T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BIIB REV | LLY REV | BIIB GROSS % | LLY GROSS % | BIIB FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $9.89B | $65.18B | 75.7% | 83.0% | $2.05B | $16.81B |
| FY 2024 | $9.68B | $45.04B | 76.1% | 81.3% | $2.72B | $8.82B |
| FY 2023 | $9.84B | $34.12B | 44.0% | 79.3% | $1.10B | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BIIB // BETA 1.10
LLY // BETA 0.51